Cargando…

The Pattern of Fasting and Post 75 G Glucose Loading of Glucagon-Like Peptide 1 Levels in Obese and Non-Obese Subjects

BACKGROUND: Prevalence of obesity increased sharply recently; it was associated with an increased prevalence of several cardiometabolic diseases. Reduced glucagon-like peptide 1 (GLP-1) secretion is observed among obese subjects in many studies, and it may mediate the failure of insulin secretion re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nugraha, Ida Bagus Aditya, Saraswati, Made Ratna, Suastika, Ketut
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Republic of Macedonia 2019
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390137/ https://www.ncbi.nlm.nih.gov/pubmed/30834001 http://dx.doi.org/10.3889/oamjms.2019.030

Ejemplares similares

The low level of glucagon-like peptide-1 (glp-1) is a risk factor of type 2 diabetes mellitus
por: Lastya, Agus, et al.
Publicado: (2014)

Factors Associated with Diabetes-Related Distress in Type 2 Diabetes Mellitus Patients
por: Bhaskara, Gilang, et al.
Publicado: (2022)

Vaspin in Developing Obesity (Vande-Ob); the Correlation of Waist Circumference and Visceral Fat Percentage with Vaspin Levels in Patients with Type II Diabetes Mellitus
por: Dwipayana, I Made Pande, et al.
Publicado: (2019)

Association of beta3-adrenergic receptor (ADRB3) Trp64Arg gene polymorphism with obesity and metabolic syndrome in the Balinese: a pilot study
por: Malik, Safarina G, et al.
Publicado: (2011)

Challenging Diagnosis of Addison's Disease Presenting with Adrenal Crisis
por: Wina Dharmesti, Ni Wayan, et al.
Publicado: (2021)

Uncoupling protein 2 gene polymorphisms are associated with obesity
por: Oktavianthi, Sukma, et al.
Publicado: (2012)

Association of Apolipoprotein E Gene Polymorphism with Lipid Profile and Ischemic Stroke Risk in Type 2 Diabetes Mellitus Patients
por: Maratni, Ni Putu Tesi, et al.
Publicado: (2021)

Chaperone-Based Therapeutic Target Innovation: Heat Shock Protein 70 (HSP70) for Type 2 Diabetes Mellitus
por: Mulyani, W. Riski Widya, et al.
Publicado: (2020)

Transcription factor 7-like 2 single nucleotide polymorphisms rs290487 and rs290481 are associated with dyslipidemia in the Balinese population
por: Limardi, Prisca C., et al.
Publicado: (2022)

Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity
por: Zaffina, Isabella, et al.
Publicado: (2023)

Dyslipidemia in diabetes: a population-based study in Bali
por: Suastika, Ketut, et al.
Publicado: (2019)

Glucagon and other proglucagon-derived peptides in the pathogenesis of obesity
por: Holst, Jens Juul
Publicado: (2022)

Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
por: Pocai, Alessandro, et al.
Publicado: (2009)

Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity
por: Anandhakrishnan, Ananthi, et al.
Publicado: (2016)

Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity
por: Williams, David M, et al.
Publicado: (2022)

Effects of Glucagon-Like-Peptide-1 Analogue Treatment in Genetic Obesity
por: Welling, Mila Sofie, et al.
Publicado: (2021)

Incretin responses to oral glucose load in Japanese non-obese healthy subjects
por: Nagai, Etsuko, et al.
Publicado: (2011)

Potential of a glucagon‐like peptide‐1 receptor/glucose‐dependent insulinotropic polypeptide receptor/glucagon receptor triagonist for the treatment of obesity and type 2 diabetes
por: Araki, Eiichi, et al.
Publicado: (2022)

Plasma gastric inhibitory polypeptide and glucagon‐like peptide‐1 levels after glucose loading are associated with different factors in Japanese subjects
por: Harada, Norio, et al.
Publicado: (2010)

Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity
por: Yazıcı, Dilek, et al.
Publicado: (2022)

Impaired Secretion of Total Glucagon-like Peptide-1 in People with Impaired Fasting Glucose Combined Impaired Glucose Tolerance
por: Zhang, Fang, et al.
Publicado: (2012)

Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates kidney injury in murine models of obesity and diabetes mellitus
por: Patel, Vishal J, et al.
Publicado: (2018)

Reversal of Obesity and Insulin Resistance by a Non-Peptidic Glucagon-Like Peptide-1 Receptor Agonist in Diet-Induced Obese Mice
por: He, Min, et al.
Publicado: (2010)

Effects of glucagon-like peptide-1 receptor agonists on glucose excursion and inflammation in overweight or obese type 2 diabetic patients
por: Huang, Xiao-Min, et al.
Publicado: (2023)

Plasma interleukin 8 concentrations in obese subjects with impaired glucose tolerance.
por: Straczkowski, Marek, et al.
Publicado: (2003)

Impaired fasting glucose levels in overweight or obese subjects for screening of type 2 diabetes in Korea
por: Lee, Jin-Hee, et al.
Publicado: (2021)

Polymorphisms of Aldose Reductase (ALR2) Regulatory Gene are Risk Factors for Diabetic Retinopathy in Type-2 Diabetes Mellitus Patients in Bali, Indonesia
por: Wihandani, Desak Made, et al.
Publicado: (2018)

The “Lipid Accumulation Product” Is Associated with 2-Hour Postload Glucose Outcomes in Overweight/Obese Subjects with Nondiabetic Fasting Glucose
por: Malavazos, Alexis Elias, et al.
Publicado: (2015)

Ingestion of Diet Soda Before a Glucose Load Augments Glucagon-Like Peptide-1 Secretion
por: Brown, Rebecca J., et al.
Publicado: (2009)

Ruptured sinus of Valsalva aneurysm coexisted with congenital ventricular septal defect: a case series
por: Sari, Ni Made Ayu Wulan, et al.
Publicado: (2023)

Laminarin counteracts diet-induced obesity associated with glucagon-like peptide-1 secretion
por: Yang, Liusong, et al.
Publicado: (2017)

Usage of Glucagon-Like Peptide-1 for Obesity in Children; Updated Review of Clinicaltrials.gov
por: Alorfi, Nasser M, et al.
Publicado: (2023)

Metabolic responses to acute sprint interval exercise training performed after an oral 75‐gram glucose load in individuals with overweight/obesity
por: Carrillo‐Arango, Hugo Alejandro, et al.
Publicado: (2023)

Effects of Roux-en-Y gastric bypass on fasting and postprandial inflammation-related parameters in obese subjects with normal glucose tolerance and in obese subjects with type 2 diabetes
por: Lindegaard, Kirsten Katrine, et al.
Publicado: (2015)

The molecular pharmacology of glucagon agonists in diabetes and obesity
por: Novikoff, Aaron, et al.
Publicado: (2023)

Glucagon‐like peptide‐1 and cholecystokinin production and signaling in the pancreatic islet as an adaptive response to obesity
por: Linnemann, Amelia K, et al.
Publicado: (2016)

The effect of meal composition on postprandial glucagon-like peptide-1 response in overweight/obese participants
por: Franklin, Brian, et al.
Publicado: (2015)

An impaired glucagon-like peptide-1 response is associated with prediabetes in polycystic ovary syndrome with obesity
por: Ferjan, Simona, et al.
Publicado: (2019)

Effects of glucagon‐like peptide‐1 analogue treatment in genetic obesity: A case series
por: Welling, Mila S., et al.
Publicado: (2021)

Jugular bulb oxygen saturation correlates with Full Outline of Responsiveness score in severe traumatic brain injury patients
por: Senapathi, Tjokorda Gde Agung, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_mq632e1qo2qo76q4b5ibqkn7ae